Treatment with melphalan, thalidomide and totiplatin has a response rate of 74% in newly diagnosed myeloma. However this therapy can only be regarded as being reasonably curative. The authors feel this treatment is curative if administered in the first 6 months of diagnosis. A combination of low-dose treatment with splenectomy (spares bone marrow) and treatment during the maintenance phase may prolong survival over 2 years. Long-term follow up of this cohort, particularly with respect to relapse, is now necessary.
The number of people with multiple myeloma is low, and it remains the same for more than a decade now. But the number of people diagnosed is increasing. There is a higher rate of people diagnosed with multiple myeloma in the United States than in Europe. This may be due to the increase in incidence of multiple myeloma and the early detection of the disease.
Many signs and symptoms of multiple myeloma are non-specific and are generally non-empathic in a patient who needs to be suspected of having MMM. Specific signs are only found when further medical investigation is required.
The most common treatment for MM is chemotherapy, and other treatments include autologous stem cell transplantation and radioimmunotherapy. In most cases, more than one treatment method is used to treat MM, and one of the main challenges for research investigators is to identify the most effective methodology for treating patients.
Once thought of solely as a tumor, multiple myeloma has also developed strong associations with both monoclonal paraproteinemias and multiple forms of amyloidoses. A single diagnosis of multiple myeloma is not always associated with one of the paraproteinemias or amyloidoses. The most common form of multiple myeloma is monoclonal gammopathy, which itself is an extremely varied disease with strong patient and genetic differences (see above).
Although [multiple myeloma](https://www.withpower.com/clinical-trials/multiple-myeloma) most commonly affects older men and current smokers, the disease can be initiated at any age or gender. Other risk factors and a strong genetic base also contribute to the development of multiple myeloma. Most myeloma begins as a precursor lesion, which progresses to a fully formed malignant neoplasm.\n
These data imply that the probability of survival is determined early on by the amount and frequency with which patients respond to a given treatment. Survival is best if patients receive treatment early. Findings from a recent study might have important ramifications for patient care.
Daratumumab is effective in treating patients with relapsed or refractory MM with or without a history of renal impairment. Daratumumab had the greatest magnitude of effect at 24 weeks.
The 5-year survival interval between the initial diagnosis of MM and the diagnosis of a secondary neoplasm (other than MDS) was 0.6 years, compared with 21.2 years with initial presentation of MDS. Survival interval was longer in patients diagnosed with the same category of MM on the bone marrow biopsy (0.6 years) compared with those with myelodysplastic syndromes (0.9 years).
Almost all patients in clinical trials were in relapsing phases of the disease. However, only 11% of patients reported baseline disease severity in the form of ISS and/or bone-only, bone and soft tissue disease. We believe these data indicate that further refinement of patient selection criteria for clinical trials would likely provide an increased number of patients eligible for these studies.
There is no cure for multiple myeloma; the only promising treatments are high-dose chemotherapy and autologous stem-cell transplantation. However, newer treatments, such as thalidomide, proteasome inhibitors, and bortezomib are still being tested to further improve the survival of patients with multiple myeloma. There are clinical trials near you for this condition. To find a clinical trial near you, visit the Power! website using the location or condition box near the top of the page.
We demonstrated a strong concordance between MDS and AML, and the MM was not attributed to MDS but to new MM events. Results from a recent paper do not necessarily imply a genetic or genetic environmental relationship between the MM and the MDS.